Crinetics Presents Clinical and Research Results at ENDO 2022

Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the selection of CRN04894 for oral presentation at ENDO 2022. This investigational drug targets conditions like Cushing’s disease and reduces serum cortisol levels and urine free cortisol excretion. Details include an oral session on June 12, 2022, highlighting the inhibition of ACTH-stimulated cortisol secretion. Additionally, results for CRN04777 and a preclinical PTH antagonist will be presented through narrated posters. These events underscore Crinetics' commitment to advancing treatments for rare endocrine diseases.

Positive

• CRN04894 showed significant reduction of serum cortisol levels and urine free cortisol, indicating promising efficacy.
• The selection for oral presentation at ENDO 2022 enhances the visibility and credibility of CRN04894 in the pharmaceutical community.

Negative

• None.

CRN04894 Selected for Oral Presentation

SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational candidate for the treatment of Cushing’s disease, congenital adrenal hyperplasia (CAH) and other conditions driven by excess adrenocorticotropic hormone (ACTH), were selected for an oral presentation at ENDO 2022, the Endocrine Society’s annual meeting. Crinetics recently reported that administration of CRN04894 reduced both serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations in multiple-ascending dose cohorts of a Phase 1 study.

Results from the company’s Phase 1 study of CRN04777, the company’s investigational candidate for the treatment of congenital hyperinsulinism (HI) will be presented as a narrated “Poster Plus.” A late-breaking Poster Plus will also be presented on the company’s preclinical-stage parathyroid hormone (PTH) antagonist for the treatment of hypercalcemia. Poster Plus presenters will participate in Meet-and-Greet sessions and their posters will be accompanied by 5-minute videos for attendees.

Presentation details:
Title:	(OR12) Inhibition of Basal and ACTH-Stimulated Cortisol Secretion in Humans Using an Oral, Nonpeptide ACTH Antagonist (CRN04894)
Time:	Sunday, June 12, 2022 11:15 a.m. - 11:30 a.m. ET
Location:	Oral Session; A404-A405
Title:	(PSUN304) CRN04777, an Oral, Nonpeptide SST5-selective Somatostatin Agonist Dose Dependently Suppresses Basal and Stimulated Insulin Secretion
Time:	Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m. ET
Location:	Poster+ Session; Hall A1
Title:	(LBSAT142) Discovery and Characterization of a Potent and Orally Bioavailable Parathyroid Hormone Receptor Type-1 (PTHR1) Antagonist for the Treatment of Hypercalcemia
Time:	Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m. ET
Location:	Poster+ Session; Hall A1

The posters and oral presentations will be made available on the Crinetics website in accordance with the congress’ embargo policy. For attendees of ENDO 2022, Crinetics staff will be available to address questions and discuss pipeline programs at the company booth (#822) and in the virtual exhibit hall.

About Crinetics Pharmaceuticals  
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine, a somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in Phase 1 clinical studies for CRN04777, a somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, and CRN04894, an ACTH antagonist for the treatment of Cushing’s disease, congenital adrenal hyperplasia, and other diseases of excess ACTH. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.

Contacts: 
Chas Schultz 
VP, IR & Corporate Communications 
cschultz@crinetics.com 
(858) 450-6464 

Investors / Media: 
Corey Davis 
LifeSci Advisors, LLC 
cdavis@lifesciadvisors.com
(212) 915-2577 

Aline Sherwood 
Scienta Communications 
asherwood@scientapr.com
(312) 238-8957 

FAQ

What is CRN04894 and what conditions does it target?

CRN04894 is an investigational drug by Crinetics Pharmaceuticals targeting Cushing’s disease and related conditions driven by excess ACTH.

When will CRN04894 be presented at ENDO 2022?

The presentation for CRN04894 will take place on June 12, 2022, from 11:15 a.m. to 11:30 a.m. ET.

What results were reported for CRN04894?

Results indicated that CRN04894 effectively reduced serum cortisol levels and 24-hour urine free cortisol in patients.

What is the significance of ENDO 2022 for Crinetics Pharmaceuticals?

ENDO 2022 provides a platform for Crinetics to showcase its advancements in endocrine treatments and gain feedback from experts.